TJ Biopharma

Hangzhou, China · Founded 2016 · Privately Held (backing)

Developer of biotechnology therapies specializing in autoimmune diseases, immuno-oncology, and metabolic disorders. TJ Biopharma is based in Hangzhou, China and was founded in 2016. Its last reported valuation was $459 million in Sep 2025. It has raised $84.2 million.

Last reported valuation
$459.2M
Oct 2026
Priced at
—
Total raised
$84.2M
Last round
—

Who backs TJ Biopharma?

13 investors
InvestorType
HSG (Hong Kong)Other
CICC CapitalPE / buyout
Oriental Fortune CapitalVenture capital
Tailong VCOther
Heda VenturesOther
Yijing CapitalVenture capital
Hangzhou Industrial Investment GroupOther
Zhuzhou SAH Innovation & Entrepreneur InvestmentOther
ENN Energy Holdings—
Shanghai Qilan Asset Management—
+ 3 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

TJ Biopharma investors

13 investors are on record for TJ Biopharma, including HSG (Hong Kong), CICC Capital, Oriental Fortune Capital and Tailong VC.

Free account
More of TJ Biopharma with a free account
  • ·The complete investor list: 13 names
  • ·Watch TJ Biopharma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 13 firms already write checks for companies like TJ Biopharma. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View